Integra LifeSciences Holdings (IART) Balance Sheet
A balance sheet shows what a company owns and owes, and shareholders' equity, at a single point in time.
Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical, ear, nose, throat, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology.
Total Assets Chart for Integra LifeSciences Holdings
Integra LifeSciences Holdings (IART) total assets for FY2025 were USD 3.6B, a -10.8% change from FY2024. Integra LifeSciences Holdings's total assets grew from USD 19.4M in 1995 to USD 3.6B in 2025 (18467.0% over 30 years). Total assets compound annual growth rate: 5-year CAGR of -0.1%, 10-year CAGR of 7.3%, 20-year CAGR of 11.0%.
Total Assets (US Dollars)
R&D as % of Revenue
Compare with
Key Stats
- Market Cap
- $926.27M
- Implied Share Price
- $11.91
- Enterprise Value
- $3.02B
- Revenue (TTM)
- $1.66B
- EBITDA
- $311.51M
- Profit Margin
- 0.79%
- Trailing P/E
- 70.06
- Forward P/E
- 6.00
- Price/Book (MRQ)
- 1.19
- Price/Sales (TTM)
- 0.56
- EV/EBITDA
- 12.32
- EV/Revenue
- 1.83
- Dividend Yield
- —
- Book Value
- $13.41
- Free Cash Flow (FY2025)
- -$45.25M
- Free Cash Flow Yield
- -4.89%
Snapshot as of 24th October 2026 — not point-in-time controlled, may lag the live market by a few days.